Immunogenicity of Salmonella vector vaccines expressing SBR of Streptococcus mutans under the control of a T7-nirB (dual) promoter system

Vaccine
M A SalamSuzanne M Michalek

Abstract

The purpose of the present study was to determine if a Salmonella vector expressing the cloned saliva-binding region (SBR) of Streptococcus mutans or SBR linked to the A2 and B subunits of cholera toxin (CTA2/B) under the control of both the T7 and nirB promoters (T7-nirB dual promoter) was more effective in inducing mucosal and systemic anti-SBR antibody responses than Salmonella clones expressing the same antigens but under the control of either the nirB or T7 promoter. Mice were immunized by the intranasal route on days 0, 18 and 320 with Salmonella enterica serovar Typhimurium strain BRD 509 containing one of six plasmids encoding SBR or SBR-CTA2/B under the control of the T7-nirB, T7, or nirB promoter. Serum, saliva and vaginal wash samples were collected throughout the experiment and assessed for antibody activity by ELISA. Evidence is provided that Salmonella clones expressing SBR or SBR-CAT2/B under the control of either the T7 or T7-nirB promoter induced a high and persistent mucosal and systemic anti-SBR antibody response. All Salmonella clones induced good anti-SBR responses following the boost on day 320.

References

Jun 1, 1992·Immunology Today·C F KuperT Sminia
Oct 1, 1990·Immunological Reviews·J G TewA K Szakal
Nov 3, 1988·Nature·D Gray, H Skarvall
May 1, 1974·The Journal of Experimental Medicine·P B Carter, F M Collins
Jan 1, 1980·Immunological Reviews·T E MandelJ G Tew
Apr 16, 1999·Oral Microbiology and Immunology·G Hajishengallis, S M Michalek
May 28, 2004·Ageing Research Reviews·Yüksel AydarAndras K Szakal
May 12, 2005·Current Opinion in Immunology·Cassy L CozineThomas J Waldschmidt

❮ Previous
Next ❯

Citations

Sep 25, 2007·International Journal of Medical Microbiology : IJMM·Cédric Cheminay, Michael Hensel
Sep 14, 2019·Letters in Applied Microbiology·M Patel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.